SCHEMBL5365822

SCHEMBL5365822

Cc1ccc(NC(=S)NN=Cc2ccc(C(=O)O)cc2O)cc1Cl

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 9/20 0.50
MAPT P10636 8/20 0.50
KDM4E B2RXH2 7/20 0.50
SMN1; SMN2 Q16637 7/20 0.50
NPC1 O15118 8/20 0.47
RAB9A P51151 7/20 0.47
ALDH1A1 P00352 7/20 0.47
HPGD P15428 2/20 0.47
THRB P10828 1/20 0.47
L3MBTL1 Q9Y468 3/20 0.47
KMT2A Q03164 4/20 0.46
MEN1 O00255 3/20 0.46
MAPK1 P28482 1/20 0.45
STAT3 P40763 1/20 0.45
STAT1 P42224 1/20 0.45
LMNA P02545 3/20 0.45
NPSR1 Q6W5P4 1/20 0.45
POLB P06746 1/20 0.45
TP53 P04637 1/20 0.44
STS P08842 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5365821 1.00 GAA (0.50) GAAMAPTKDM4ESMN1; SMN2NPC1
SCHEMBL5373019 0.86 NCOA1 (0.55) GAAMAPTKDM4ESMN1; SMN2NPC1
SCHEMBL5373013 0.86 NCOA1 (0.55) GAAMAPTKDM4ESMN1; SMN2NPC1
SCHEMBL5369530 0.80 MAPT (0.53) GAAMAPTKDM4ESMN1; SMN2NPC1
SCHEMBL5369527 0.80 MAPT (0.53) GAAMAPTKDM4ESMN1; SMN2NPC1
SCHEMBL5372739 0.75 SIRT1 (0.57) GAAMAPTKDM4ESMN1; SMN2NPC1
SCHEMBL5372745 0.75 SIRT1 (0.57) GAAMAPTKDM4ESMN1; SMN2NPC1
SCHEMBL5357801 0.74 KDM4E (0.54) GAAMAPTKDM4ESMN1; SMN2NPC1
SCHEMBL5357804 0.74 KDM4E (0.54) GAAMAPTKDM4ESMN1; SMN2NPC1
SCHEMBL5366765 0.74 MAPT (0.62) GAAMAPTKDM4ESMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1349613-A4 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORP (US) 2005-09-21 EP claimed
US-20040058990-A1 Thrombopoietin mimetics SMITHKLINE BEECHAM CORPORATION 2004-03-25 US claimed
EP-1349613-A2 THROMBOPOIETIN MIMETICS SmithKline Beecham Corporation (US) 2003-10-08 EP claimed
WO-2002049413-A2 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORPORATION (US) 2002-06-27 WO claimed
US-7241783-B2 Thrombopoietin mimetics SMITHKLINE BEECHAM CORPORATION (US) 2007-07-10 US disclosed
EP-1349613-A4 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORP (US) 2005-09-21 EP disclosed
US-20040058990-A1 Thrombopoietin mimetics SMITHKLINE BEECHAM CORPORATION 2004-03-25 US disclosed
EP-1349613-A2 THROMBOPOIETIN MIMETICS SmithKline Beecham Corporation (US) 2003-10-08 EP disclosed
WO-2002049413-A2 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORPORATION (US) 2002-06-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040058990-A1 Thrombopoietin mimetics MPL, THPO, TEK GAA 3120/4885MAPT 4635/4885KDM4E 3460/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.